Organoids and Cancer Models

A special issue of Organoids (ISSN 2674-1172).

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 1787

Special Issue Editor


E-Mail Website
Guest Editor
1. Center for Cell Reprograming, Departments of Pathology and Oncology, Georgetown University Medical Center, Washington, DC 20057, USA
2. Departments of Pathology and Urology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Interests: cell reprogramming; telomerase and telomeres; patient-derived models; cell therapies; living biobanks; viruses; cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Traditional cancer models, including cell lines and animal models, have been widely used but have seen limited applications in both basic and clinical cancer research. Patient-derived model systems are needed for modeling human diseases and precision medicine. Genomics-based precision oncology only helps 2–20% of patients with solid cancer, and as such, functional diagnostics and patient-derived models are needed for precision cancer biology. Induced pluripotent stem cells (iPS), organoids, and conditional reprogramming (CR) are currently used widely for patient-derived cell models for disease and precision medicine. Both organoids and CR technologies have been cited in two NCI programs, the PDMR (Patient-Derived Cancer Model Repository) and HCMI (Human Cancer Models Initiative), the latter of which will be distributed through the ATCC. These cells can be easily manipulated in vitro, and thus, these patient-derived cells could be used for next-generation disease models. In this Special Issue, we will focus on the applications of organoids and other reprogrammed cells in cancer modeling and drug discovery.

Prof. Dr. Xuefeng Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Organoids is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • patient-derived cells
  • organoids
  • iPS (induced pluripotent stem cells)
  • CRC (conditionally reprogrammed cells)
  • air–liquid interface cultures
  • circulating tumor cells
  • cancer modeling
  • drug discovery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

9 pages, 5929 KiB  
Study Protocol
A Method to Study Migration and Invasion of Mouse Intestinal Organoids
by Valérie M. Wouters, Ciro Longobardi and Jan Paul Medema
Organoids 2024, 3(3), 194-202; https://doi.org/10.3390/organoids3030013 - 21 Aug 2024
Viewed by 1073
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide and it is the second leading cause of cancer death. In CRC, as in most cancers, the formation of metastasis through the migration and invasion of cancer cells to distant organs is associated [...] Read more.
Colorectal cancer (CRC) is the third most common cancer worldwide and it is the second leading cause of cancer death. In CRC, as in most cancers, the formation of metastasis through the migration and invasion of cancer cells to distant organs is associated with a dismal prognosis. The study of the mechanisms associated with cancer, and, in particular, CRC, changed in the last decade due to the introduction of organoids. These represent a step forward in terms of complexity from cell lines and allowed the use of mouse models in cancer research to be limited. Although organoids faithfully model the cellular complexity of CRC, current protocols do not allow for the use of organoids in some crucial processes of metastasis, such as migration and invasion. In this study, a method to study migration and invasion using mouse intestinal organoids in vitro is presented. This protocol provides researchers with the opportunity to investigate the migratory behavior of organoid lines and study the impact of distinct mutations on the migratory and invasive capacity of cancer cells. Full article
(This article belongs to the Special Issue Organoids and Cancer Models)
Show Figures

Figure 1

Back to TopTop